MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This study is testing a new drug called MiRisten in people with acute myeloid leukemia (AML) — a fast-growing blood cancer — that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with AML that has relapsed (come back) or is refractory (not responding to treatment) - You have already tried or are ineligible for available AML therapies - You are in reasonably good health (ECOG 0–2) with a life expectancy of at least 3 months - Your liver function and blood counts meet minimum required levels - Tumor tissue from your diagnosis is available (or an exception is granted) **You may NOT be eligible if...** - Your AML has spread outside the bone marrow but not back to the marrow itself - You have not yet recovered from side effects of previous treatments - You have severely impaired liver function Talk to your doctor to see if this trial is right for you.